BeiGene, Ltd. announced that Mr. Thomas Malley ("Mr. Malley") resigned as an independent non-executive director on January 22, 2024, and Dr. Olivier Brandicourt ("Dr. Brandicourt") has been appointed to the board of directors of the Company (the "Board") as an independent non-executive director, effective as of January 23, 2024. Effective as of January 22, 2024, Mr. Malley resigned from the Board. In connection with his resignation from the Board, Mr. Malley also resigned from the Audit Committee of the Board (the "Audit Committee") and the Scientific Advisory Committee of the Board.

Mr. Malley served as a member of the Board since 2016. Effective as of January 23, 2024, the Board appointed Dr. Brandicourt as an independent non-executive director to fill the vacancy arising from the resignation of Mr. Malley. Dr. Brandicourt will serve as a Class II director until the 2024 annual general meeting of shareholders of the Company to be held in June 2024 and until his successor is duly elected and qualified, subject to his earlier resignation or removal.

In connection with his appointment to the Board, effective as of January 23, 2024, Dr. Brandicourt has been appointed to serve as a member of the Audit Committee. Dr. Brandicourt, aged 67, has served as a Senior Advisor at Blackstone Life Sciences, a private equity segment of The Blackstone Group that invests within the life science sector, since November 2019. Dr. Brandicourt currently serves on the boards of Alnylam Pharmaceuticals Inc., a Nasdaq-listed commercial-stage biopharmaceutical company developing novel therapeutics based on RNAi; BenevolentAI S.A., a Euronext-listed clinical-stage AI-enabled drug discovery company; and Dewpoint Therapeutics Inc., a privately held condensate biotechnology company.

He also serves as chair of the board of AvenCell Therapeutics Inc., a privately held leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic engineered CAR-T cell therapies. Dr. Brandicourt has over 30 years of experience in the global pharmaceutical industry, including as a senior leader of three global pharmaceutical companies. From April 2015 to August 2019, Dr. Brandicourt served as Chief Executive Officer and a member of the board of directors of Sanofi S.A. Prior to Sanofi, he was the Chief Executive Officer and Chair of Bayer HealthCare AG from November 2013 to March 2015.

From 2000 to 2013, Dr. Brandicourt served in various operational and managerial positions at Pfizer Inc., including as a member of the Executive Leadership Team and President and General Manager of the Emerging Markets and Established Products Business Units. During his tenure at Sanofi, Dr. Brandicourt was elected Chairman of the Board of Management of the Pharmaceutical Research and Manufacturers of America in 2019 and Vice-President of the European Federation of Pharmaceutical Industries and Associations, serving from 2017 to 2019. He is an Honorary Fellow of the Royal College of Physicians in London.

Dr. Brandicourt studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine and holds a Master's Degree in Biology from Paris XII University and an Advanced Degree in Cellular and Immunological Pathophysiology from the Paris Descartes University.